Japan Approves Myriad’s MyChoice Test for Prostate Cancer with Lynparza
Japan’s Ministry of Health, Labour and Welfare approved Myriad Genetics’ MyChoice Test as a companion diagnostic for Lynparza in prostate cancer patients. The decision extends National Health Insurance coverage beyond breast and ovarian indications, enabling genomic testing for over 100,000 newly diagnosed men and potentially increasing Myriad’s diagnostic revenues.
1. Approval Details
Japan’s Ministry of Health, Labour and Welfare has granted approval for Myriad Genetics’ MyChoice Test to serve as a companion diagnostic for Lynparza (olaparib) in prostate cancer patients. This authorization allows clinicians to assess homologous recombination deficiency and BRCA1/2 status in prostate tumors, aligning with existing ovarian, breast, and prostate indications.
2. Insurance Reimbursement
Under Japan’s National Health Insurance, MyChoice testing was previously reimbursed only for breast and ovarian cancer. The expanded coverage now includes prostate cancer, broadening access to comprehensive genomic profiling for a new patient cohort.
3. Market Implications
With over 100,000 men diagnosed annually in Japan and a subset progressing to metastatic castration-resistant disease, the approval could significantly raise test volumes and expand the pool of patients eligible for PARP inhibitor therapies, driving growth in Myriad’s Cancer Care Continuum portfolio.